A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve?

ABSTRACT: To investigate the potential treatment evolution and outcome improvement, we retrospectively compared clinical characteristics, therapeutic strategies, treatment responses, and overall survival (OS) in patients diagnosed and treated with lymphoma-associated HLH between 2004-2012 (n = 30) and 2013-2021 (n = 26). Our study showed that the clinical characteristics of lymphoma-associated HLH did not substantially change over the past two decades. However, more patients diagnosed in 2013-2021 were tested for Epstein-Barr virus than those diagnosed in 2004-2012 (69.3% vs. 33.3%; p = 0.021). In addition, Eastern Cooperative Oncology Group performance status 3-4 (hazard ratio (HR): 5.38; 95% confidence intervals (CI): 2.49-11.61; p < 0.001) and jaundice (HR: 2.91; 95% CI: 1.37-6.18; p = 0.006) wer

SUBMITTER: Lin CH 

PROVIDER: S-EPMC8584765 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature